Dr Yi Lin from Mayo Clinic, Rochester, USA describes the results of the ZUMA-1 trial in patients with refractory non-Hodgkin lymphoma (NHL), who currently have a very poor outcome. The study met it’s primary endpoint with regard to response rate and the investigators found common immunotherapy toxicities and side effects, which they felt were manageable and tolerable. This video was recorded at the European Society of Hematology meeting in Madrid, Spain.